HK Stock Market Move | CANBRIDGE-B(01228) has risen by nearly 35%. The company is actively preparing for the negotiation of healthcare insurance in GeRuiNing and promoting the product's overseas market entry process.

CANBRIDGE-B(01228) has risen by nearly 35%, with a cumulative increase of 300% since the beginning of June. As of the time of writing, it has risen by 25.58% to 0.54 Hong Kong dollars, with a trading volume of 12.8774 million Hong Kong dollars. On the news front, Beihai Kangcheng announced that on May 13th, the domestically developed enzyme replacement therapy drug Gorillamid for Goucher disease patients aged 12 and above with type I and III received its first prescription at Xinhua Hospital, affiliated with Shanghai Jiaotong University School of Medicine. This marks the official entry of this domestically developed enzyme replacement drug into clinical use. Dr. Xue Qun, founder, chairman, and CEO of Beihai Kangcheng, previously stated at a media communication meeting that, although he could not disclose the specific pricing, he could promise that the pricing of Gorillamid upon market launch would be significantly reduced, with an expected price reduction of at least 50% compared to existing therapies of the same kind. Therefore, with potential advantages in pricing, medical insurance coverage, and patient services, Veligenase Beta is expected to improve the accessibility of medications and benefit more patients. It is reported that in addition to actively preparing for this year's medical insurance negotiation for Gorillamid, Beihai Kangcheng will also accelerate the overseas launch of this product in the next step.